Download PDF
Am J Perinatol 2018; 35(13): 1241-1250
DOI: 10.1055/s-0038-1653944
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Past and Present: A Review of Antenatal Corticosteroids and Recommendations for Late Preterm Birth Steroids

C. Luke Dixon
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Gloria Too
2   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
George R. Saade
1   Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, Texas
,
Cynthia Gyamfi-Bannerman
3   Department of Obstetrics and Gynecology, Columbia University, New York, New York
› Author Affiliations
Further Information

Publication History

22 December 2017

08 April 2018

Publication Date:
23 May 2018 (online)

   Permissions and Reprints

Abstract

Since 1972, the beneficial neonatal effects of antenatal corticosteroids (ACSs) have been repeatedly demonstrated in pregnancies at risk of preterm birth before 34 weeks' gestation. While ACS utilization before 34 weeks has been high since the 1990s, knowledge gaps regarding the risks and benefits of ACS continue to exist. Recent evidence has been published regarding the benefit of ACS in the late preterm period. This review addresses the evidence and knowledge gaps for ACS use before and after 34 weeks' gestation. We also provide recommendations for ACS use in the late preterm period.

Keywords

antenatal corticosteroids - betamethasone - dexamethasone - fetal - maturity - late preterm steroids

Supplementary Material

 

  • References

  • 1 Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50 (04) 515-525
    Google Scholar
  • 2 Papageorgiou AN, Colle E, Farri-Kostopoulos E, Gelfand MM. Incidence of respiratory distress syndrome following antenatal betamethasone: role of sex, type of delivery, and prolonged rupture of membranes. Pediatrics 1981; 67 (05) 614-617
    PubMedGoogle Scholar
  • 3 NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995; 273 (05) 413-418
    CrossrefPubMedGoogle Scholar
  • 4 Block MF, Kling OR, Crosby WM. Antenatal glucocorticoid therapy for the prevention of respiratory distress syndrome in the premature infant. Obstet Gynecol 1977; 50 (02) 186-190
    PubMedGoogle Scholar
  • 5 Crowley P, Chalmers I, Keirse MJ. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1990; 97 (01) 11-25
    Google Scholar
  • 6 Committee on Obstetric Practice. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2002; 99 (5 Pt 1): 871-873
    PubMedGoogle Scholar
  • 7 Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454
    PubMedGoogle Scholar
  • 8 Ecker JL, Kaimal A, Mercer BM. , et al; American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine. #3: Periviable birth. Am J Obstet Gynecol 2015; 213 (05) 604-614
    CrossrefPubMedGoogle Scholar
  • 9 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126 (03) 443-456
    CrossrefPubMedGoogle Scholar
  • 10 Younge N, Goldstein RF, Bann CM. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Survival and neurodevelopmental outcomes among periviable infants. N Engl J Med 2017; 376 (07) 617-628
    CrossrefPubMedGoogle Scholar
  • 11 Carlo WA, McDonald SA, Fanaroff AA. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306 (21) 2348-2358
    Google Scholar
  • 12 Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J. Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants. Am J Perinatol 2010; 27 (01) 61-66
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Wong D, Abdel-Latif M, Kent A. ; NICUS Network. Antenatal steroid exposure and outcomes of very premature infants: a regional cohort study. Arch Dis Child Fetal Neonatal Ed 2014; 99 (01) F12-F20
    CrossrefPubMedGoogle Scholar
  • 14 Miltaha HR, Fahey LM, Sajous CH, Morrison JC, Muraskas JK. Influence of perinatal factors in short- and long-term outcomes of infants born at 23 weeks of gestation. Am J Perinatol 2015; 32 (07) 627-632
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hayes EJ, Paul DA, Stahl GE. , et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. Obstet Gynecol 2008; 111 (04) 921-926
    CrossrefPubMedGoogle Scholar
  • 16 Raju TN, Mercer BM, Burchfield DJ, Joseph Jr GF. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists. Obstet Gynecol 2014; 123 (05) 1083-1096
    CrossrefPubMedGoogle Scholar
  • 17 Eunice Kennedy Shriver National Institure of Child Health and Human Development. NICHD Neonatal Research Network (NRN): Extremely Preterm Birth Outcome Data. Available at: https://www1.nichd.nih.gov/epbo-calculator/Pages/epbo_case.aspx . Accessed April 1, 2018
    PubMedGoogle Scholar
  • 18 Mitsiakos G, Kovacs L, Papageorgiou A. Are antenatal steroids beneficial to severely growth restricted fetuses?. J Matern Fetal Neonatal Med 2013; 26 (15) 1496-1499
    CrossrefPubMedGoogle Scholar
  • 19 Riskin-Mashiah S, Riskin A, Bader D. , et al; Israel Neonatal Network. Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24-31 weeks' gestation: a population-based study. BJOG 2016; 123 (11) 1779-1786
    CrossrefPubMedGoogle Scholar
  • 20 Torrance HL, Derks JB, Scherjon SA, Wijnberger LD, Visser GH. Is antenatal steroid treatment effective in preterm IUGR fetuses?. Acta Obstet Gynecol Scand 2009; 88 (10) 1068-1073
    CrossrefPubMedGoogle Scholar
  • 21 Niroomanesh S, Shojaei K, Moghadam SF, Mohammadi N, Rahimi Z, RezaeiKeyhanaei K. Effect of prenatal betamethasone on fetal, uteroplacental, and maternal blood flow velocity in pregnancies complicated by fetal growth restriction. Int J Gynaecol Obstet 2015; 130 (03) 270-273
    CrossrefPubMedGoogle Scholar
  • 22 Nozaki AM, Francisco RP, Fonseca ES, Miyadahira S, Zugaib M. Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2009; 88 (03) 350-354
    CrossrefPubMedGoogle Scholar
  • 23 Robertson MC, Murila F, Tong S, Baker LS, Yu VY, Wallace EM. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113 (03) 636-640
    CrossrefPubMedGoogle Scholar
  • 24 Simchen MJ, Alkazaleh F, Adamson SL. , et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190 (02) 296-304
    CrossrefPubMedGoogle Scholar
  • 25 Wijnberger LD, Bilardo CM, Hecher K, Stigter RH, Visser GH. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol 2004; 23 (06) 584-589
    CrossrefPubMedGoogle Scholar
  • 26 Senat MV, Ville Y. Effect of steroids on arterial Doppler in intrauterine growth retardation fetuses. Fetal Diagn Ther 2000; 15 (01) 36-40
    CrossrefPubMedGoogle Scholar
  • 27 Vidaeff AC, Blackwell SC. Potential risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by severe fetal growth restriction. Obstet Gynecol Clin North Am 2011; 38 (02) 205-214
    CrossrefPubMedGoogle Scholar
  • 28 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; (03) CD004454
    PubMedGoogle Scholar
  • 29 Ballabh P, Lo ES, Kumari J. , et al. Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clin Pharmacol Ther 2002; 71 (01) 39-45
    CrossrefPubMedGoogle Scholar
  • 30 Gyamfi C, Mele L, Wapner RJ. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. Am J Obstet Gynecol 2010; 203 (03) 219.e1-219.e5
    CrossrefPubMedGoogle Scholar
  • 31 Committee on Obstetric Practice. Committee Opinion No. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017; 130 (02) e102-e109
    Google Scholar
  • 32 Fisher SC, Kim SY, Sharma AJ, Rochat R, Morrow B. Is obesity still increasing among pregnant women? Prepregnancy obesity trends in 20 states, 2003-2009. Prev Med 2013; 56 (06) 372-378
    CrossrefPubMedGoogle Scholar
  • 33 Branum AM, Kirmeyer SE, Gregory EC. Prepregnancy body mass index by maternal characteristics and state: data from the birth certificate, 2014. Natl Vital Stat Rep 2016; 65 (06) 1-11
    PubMedGoogle Scholar
  • 34 Shah DK, Missmer SA, Correia KF, Ginsburg ES. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014; 99 (04) 1314-1321
    CrossrefPubMedGoogle Scholar
  • 35 Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 1988; 2 (03) 239-256
    CrossrefPubMedGoogle Scholar
  • 36 Hashima JN, Lai Y, Wapner RJ. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids. Am J Obstet Gynecol 2010; 202 (03) 263.e1-263.e5
    CrossrefPubMedGoogle Scholar
  • 37 Gyamfi-Bannerman C, Son M. Preterm premature rupture of membranes and the rate of neonatal sepsis after two courses of antenatal corticosteroids. Obstet Gynecol 2014; 124 (05) 999-1003
    CrossrefPubMedGoogle Scholar
  • 38 Elimian A, Verma U, Beneck D, Cipriano R, Visintainer P, Tejani N. Histologic chorioamnionitis, antenatal steroids, and perinatal outcomes. Obstet Gynecol 2000; 96 (03) 333-336
    PubMedGoogle Scholar
  • 39 Kent A, Lomas F, Hurrion E, Dahlstrom JE. Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health 2005; 41 (04) 186-190
    CrossrefPubMedGoogle Scholar
  • 40 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 172: premature rupture of membranes. Obstet Gynecol 2016; 128 (04) e165-e177
    CrossrefPubMedGoogle Scholar
  • 41 Crowley P. Antenatal corticosteroids--current thinking. BJOG 2003; 110 (Suppl. 20) 77-78
    PubMedGoogle Scholar
  • 42 Lee BH, Stoll BJ, McDonald SA, Higgins RD. ; National Institute of Child Health and Human Development Neonatal Research Network. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006; 117 (05) 1503-1510
    CrossrefPubMedGoogle Scholar
  • 43 Feldman DM, Carbone J, Belden L, Borgida AF, Herson V. Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates. Am J Obstet Gynecol 2007; 197 (03) 284.e1-284.e4
    CrossrefPubMedGoogle Scholar
  • 44 Elimian A, Garry D, Figueroa R, Spitzer A, Wiencek V, Quirk JG. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol 2007; 110 (01) 26-30
    CrossrefPubMedGoogle Scholar
  • 45 Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2013; (08) CD006764
    PubMedGoogle Scholar
  • 46 Elimian A, Figueroa R, Spitzer AR, Ogburn PL, Wiencek V, Quirk JG. Antenatal corticosteroids: are incomplete courses beneficial?. Obstet Gynecol 2003; 102 (02) 352-355
    PubMedGoogle Scholar
  • 47 McLaughlin KJ, Crowther CA, Walker N, Harding JE. Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review. Aust N Z J Obstet Gynaecol 2003; 43 (02) 101-106
    CrossrefPubMedGoogle Scholar
  • 48 Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173 (01) 322-335
    Google Scholar
  • 49 Vermillion ST, Soper DE, Newman RB. Is betamethasone effective longer than 7 days after treatment?. Obstet Gynecol 2001; 97 (04) 491-493
    PubMedGoogle Scholar
  • 50 Ring AM, Garland JS, Stafeil BR, Carr MH, Peckman GS, Pircon RA. The effect of a prolonged time interval between antenatal corticosteroid administration and delivery on outcomes in preterm neonates: a cohort study. Am J Obstet Gynecol 2007; 196 (05) 457.e1-457.e6
    CrossrefPubMedGoogle Scholar
  • 51 Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS. ; Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006; 367 (9526): 1913-1919
    CrossrefPubMedGoogle Scholar
  • 52 Guinn DA, Atkinson MW, Sullivan L. , et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA 2001; 286 (13) 1581-1587
    CrossrefPubMedGoogle Scholar
  • 53 McEvoy C, Bowling S, Williamson K. , et al. The effect of a single remote course versus weekly courses of antenatal corticosteroids on functional residual capacity in preterm infants: a randomized trial. Pediatrics 2002; 110 (2 Pt 1): 280-284
    CrossrefPubMedGoogle Scholar
  • 54 Murphy KE, Hannah ME, Willan AR. , et al; MACS Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet 2008; 372 (9656): 2143-2151
    CrossrefPubMedGoogle Scholar
  • 55 Wapner RJ, Sorokin Y, Thom EA. , et al; National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol 2006; 195 (03) 633-642
    CrossrefPubMedGoogle Scholar
  • 56 Battin M, Bevan C, Harding J. Growth in the neonatal period after repeat courses of antenatal corticosteroids: data from the ACTORDS randomised trial. Arch Dis Child Fetal Neonatal Ed 2012; 97 (02) F99-F105
    CrossrefPubMedGoogle Scholar
  • 57 Murphy KE, Willan AR, Hannah ME. , et al; Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study Collaborative Group. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol 2012; 119 (05) 917-923
    Google Scholar
  • 58 Asztalos EV, Murphy KE, Hannah ME. , et al; Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth study: 2-year outcomes. Pediatrics 2010; 126 (05) e1045-e1055
    CrossrefPubMedGoogle Scholar
  • 59 Asztalos EV, Murphy KE, Willan AR. , et al; MACS-5 Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth study: outcomes in children at 5 years of age (MACS-5). JAMA Pediatr 2013; 167 (12) 1102-1110
    Google Scholar
  • 60 Asztalos E, Willan A, Murphy K. , et al; MACS-5 Collaborative Group. Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5). BMC Pregnancy Childbirth 2014; 14: 272
    CrossrefPubMedGoogle Scholar
  • 61 Wapner RJ, Sorokin Y, Mele L. , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007; 357 (12) 1190-1198
    CrossrefPubMedGoogle Scholar
  • 62 Vermillion ST, Bland ML, Soper DE. Effectiveness of a rescue dose of antenatal betamethasone after an initial single course. Am J Obstet Gynecol 2001; 185 (05) 1086-1089
    CrossrefPubMedGoogle Scholar
  • 63 Peltoniemi OM, Kari MA, Tammela O. , et al; Repeat Antenatal Betamethasone Study Group. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. Pediatrics 2007; 119 (02) 290-298
    CrossrefPubMedGoogle Scholar
  • 64 McEvoy C, Schilling D, Peters D. , et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol 2010; 202 (06) 544.e1-544.e9
    CrossrefPubMedGoogle Scholar
  • 65 Garite TJ, Kurtzman J, Maurel K, Clark R. Obstetrix Collaborative Research Network. Impact of a ‘rescue course’ of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol 2009; 200 (03) 248.e1-248.e9
    CrossrefPubMedGoogle Scholar
  • 66 Peltoniemi OM, Kari MA, Lano A. , et al; Repeat Antenatal Betamethasone (RepeatBM) Follow-Up Study Group. Two-year follow-up of a randomised trial with repeated antenatal betamethasone. Arch Dis Child Fetal Neonatal Ed 2009; 94 (06) F402-F406
    CrossrefPubMedGoogle Scholar
  • 67 Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2011; (06) CD003935
    PubMedGoogle Scholar
  • 68 Peltoniemi OM, Kari MA, Hallman M. Repeated antenatal corticosteroid treatment: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2011; 90 (07) 719-727
    CrossrefPubMedGoogle Scholar
  • 69 McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat antenatal glucocorticoids for women at risk of preterm birth: a Cochrane Systematic Review. Am J Obstet Gynecol 2012; 206 (03) 187-194
    CrossrefPubMedGoogle Scholar
  • 70 Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006; 118 (03) 1207-1214
    CrossrefPubMedGoogle Scholar
  • 71 Darcy AE. Complications of the late preterm infant. J Perinat Neonatal Nurs 2009; 23 (01) 78-86
    PubMedGoogle Scholar
  • 72 Engle WA. Morbidity and mortality in late preterm and early term newborns: a continuum. Clin Perinatol 2011; 38 (03) 493-516
    CrossrefPubMedGoogle Scholar
  • 73 Hibbard JU, Wilkins I, Sun L. , et al; Consortium on Safe Labor. Respiratory morbidity in late preterm births. JAMA 2010; 304 (04) 419-425
    CrossrefPubMedGoogle Scholar
  • 74 Mally PV, Bailey S, Hendricks-Muñoz KD. Clinical issues in the management of late preterm infants. Curr Probl Pediatr Adolesc Health Care 2010; 40 (09) 218-233
    PubMedGoogle Scholar
  • 75 Shields JR, Resnik R. Fetal lung maturation and the antenatal use of glucocorticoids to prevent the respiratory distress syndrome. Obstet Gynecol Surv 1979; 34 (05) 343-363
    CrossrefPubMedGoogle Scholar
  • 76 Odibo IN, Bird TM, McKelvey SS, Sandlin A, Lowery C, Magann EF. Childhood respiratory morbidity after late preterm and early term delivery: a study of Medicaid patients in South Carolina. Paediatr Perinat Epidemiol 2016; 30 (01) 67-75
    CrossrefPubMedGoogle Scholar
  • 77 Voge GA, Katusic SK, Qin R, Juhn YJ. Risk of asthma in late preterm infants: a propensity score approach. J Allergy Clin Immunol Pract 2015; 3 (06) 905-910
    CrossrefPubMedGoogle Scholar
  • 78 Abe K, Shapiro-Mendoza CK, Hall LR, Satten GA. Late preterm birth and risk of developing asthma. J Pediatr 2010; 157 (01) 74-78
    CrossrefPubMedGoogle Scholar
  • 79 Ventolini G, Neiger R, Mathews L, Adragna N, Belcastro M. Incidence of respiratory disorders in neonates born between 34 and 36 weeks of gestation following exposure to antenatal corticosteroids between 24 and 34 weeks of gestation. Am J Perinatol 2008; 25 (02) 79-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Eriksson L, Haglund B, Ewald U, Odlind V, Kieler H. Health consequences of prophylactic exposure to antenatal corticosteroids among children born late preterm or term. Acta Obstet Gynecol Scand 2012; 91 (12) 1415-1421
    CrossrefPubMedGoogle Scholar
  • 81 Shanks A, Gross G, Shim T, Allsworth J, Sadovsky Y, Bildirici I. Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. Am J Obstet Gynecol 2010; 203 (01) 47.e1-47.e5
    CrossrefPubMedGoogle Scholar
  • 82 Yinon Y, Haas J, Mazaki-Tovi S. , et al. Should patients with documented fetal lung immaturity after 34 weeks of gestation be treated with steroids?. Am J Obstet Gynecol 2012; 207 (03) 222.e1-222.e4
    Google Scholar
  • 83 Kamath-Rayne BD, DeFranco EA, Marcotte MP. Antenatal steroids for treatment of fetal lung immaturity after 34 weeks of gestation: an evaluation of neonatal outcomes. Obstet Gynecol 2012; 119 (05) 909-916
    CrossrefPubMedGoogle Scholar
  • 84 Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ 2011; 342: d1696
    CrossrefPubMedGoogle Scholar
  • 85 Balci O, Ozdemir S, Mahmoud AS, Acar A, Colakoglu MC. The effect of antenatal steroids on fetal lung maturation between the 34th and 36th week of pregnancy. Gynecol Obstet Invest 2010; 70 (02) 95-99
    CrossrefPubMedGoogle Scholar
  • 86 Gyamfi-Bannerman C, Thom EA, Blackwell SC. , et al; NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14) 1311-1320
    CrossrefPubMedGoogle Scholar
  • 87 Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006; 367 (9520): 1421-1431
    Google Scholar
  • 88 Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 1: Outcomes. Nat Rev Endocrinol 2014; 10 (07) 391-402
    Google Scholar
  • 89 Singh RR, Cuffe JS, Moritz KM. Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. Clin Exp Pharmacol Physiol 2012; 39 (11) 979-989
    CrossrefPubMedGoogle Scholar
  • 90 Dalziel SR, Lim VK, Lambert A. , et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 2005; 331 (7518): 665
    CrossrefPubMedGoogle Scholar
  • 91 Dalziel SR, Walker NK, Parag V. , et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 2005; 365 (9474): 1856-1862
    CrossrefPubMedGoogle Scholar
  • 92 Dalziel SR, Rea HH, Walker NK. , et al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax 2006; 61 (08) 678-683
    CrossrefPubMedGoogle Scholar
  • 93 Ng PC, Wong GW, Lam CW. , et al. Effect of multiple courses of antenatal corticosteroids on pituitary-adrenal function in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 80 (03) F213-F216
    CrossrefPubMedGoogle Scholar
  • 94 Buyukkayhan D, Ozturk MA, Kurtoglu S, Koklu E, Yikilmaz A. Effect of antenatal betamethasone use on adrenal gland size and endogenous cortisol and 17-hydroxyprogesterone in preterm neonates. J Pediatr Endocrinol Metab 2009; 22 (11) 1027-1031
    PubMedGoogle Scholar
  • 95 Davis EP, Waffarn F, Sandman CA. Prenatal treatment with glucocorticoids sensitizes the hpa axis response to stress among full-term infants. Dev Psychobiol 2011; 53 (02) 175-183
    CrossrefPubMedGoogle Scholar
  • 96 Ashwood PJ, Crowther CA, Willson KJ. , et al. Neonatal adrenal function after repeat dose prenatal corticosteroids: a randomized controlled trial. Am J Obstet Gynecol 2006; 194 (03) 861-867
    CrossrefPubMedGoogle Scholar
  • 97 Alexander N, Rosenlöcher F, Stalder T. , et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab 2012; 97 (10) 3538-3544
    CrossrefPubMedGoogle Scholar
  • 98 Marinoni E, Letizia C, Ciardo F, Corona G, Moscarini M, Di Iorio R. Effects of prenatal betamethasone administration on leptin and adiponectin concentrations in maternal and fetal circulation. Am J Obstet Gynecol 2008; 199 (02) 141.e1-141.e6
    CrossrefPubMedGoogle Scholar
  • 99 Pettit KE, Tran SH, Lee E, Caughey AB. The association of antenatal corticosteroids with neonatal hypoglycemia and hyperbilirubinemia. J Matern Fetal Neonatal Med 2014; 27 (07) 683-686
    Google Scholar
  • 100 Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics 2000; 105 (06) E77
    CrossrefPubMedGoogle Scholar
  • 101 Alexander N, Rosenlöcher F, Dettenborn L. , et al. Impact of antenatal glucocorticoid therapy and risk of preterm delivery on intelligence in term-born children. J Clin Endocrinol Metab 2016; 101 (02) 581-589
    CrossrefPubMedGoogle Scholar
  • 102 Kelly BA, Lewandowski AJ, Worton SA. , et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. Pediatrics 2012; 129 (05) e1282-e1290
    CrossrefPubMedGoogle Scholar
  • 103 Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G. Neurodevelopmental outcome after a single course of antenatal steroids in children born preterm: a systematic review and meta-analysis. Obstet Gynecol 2015; 125 (06) 1385-1396
    Google Scholar
  • 104 Uno H, Lohmiller L, Thieme C. , et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res 1990; 53 (02) 157-167
    Google Scholar
  • 105 Stutchfield PR, Whitaker R, Gliddon AE, Hobson L, Kotecha S, Doull IJ. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013; 98 (03) F195-F200
    Google Scholar
  • 106 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: management of preterm labor. Obstet Gynecol 2016; 128 (04) e155-e164
    CrossrefPubMedGoogle Scholar